Home
Goldman Sachs Group reported a 7.5% stake in 4D Molecular Therapeutics FDMT · 4,286,077.48 sh · amendment · passive holder
Trade details
- Type
- 5% stake report
- Report
- 13G passive · amendment
- Stake
- 7.5%
- Last report
- 9.6% · filed 25/02/10
- Shares held
- 4,286,077.48 sh
- Class
- Common Stock, par value $0.0001 per share
- Holder
- Goldman Sachs Group
- Event date
- 25/12/31
- Filed
- 26/02/09
7.5% stake · −2.1pp from the last report
- Stake
- 7.5%
- Last report
- 9.6%
- Since last report
- −2.1pp
4D Molecular Therapeutics trades, last 26 weeks
What else happened in 4D Molecular Therapeutics around then
Filed or reported within 30 days of the trade day · 25/12/01~01/30Goldman Sachs Group's other 5% stake reports
- Goldman Sachs Group
5% stakeFuture Money Acquisition
5% stakeFuture Money Acquisition
FMAC
7.5% stake
1,184,873 sh
7.5% stake
Filed 08/14
- Goldman Sachs Group
5% stakeBreeze Acquisition Corp. II
5% stakeBreeze Acquisition Corp. II
BREZ
6.7% stake
970,701 sh
6.7% stake
Filed 08/14
- Goldman Sachs Group
5% stakeAmerican Exceptionalism Acquisition Corp. A
5% stakeAmerican Exceptionalism Acquisition Corp. A
AEXA
4.2% stake
1,444,735 sh
4.2% stake
Filed 08/14
- Goldman Sachs Group
5% stakeApex Tech Acquisition
5% stakeApex Tech Acquisition
TRAD
7.6% stake
1,076,558 sh
7.6% stake
Filed 08/14
- Goldman Sachs Group
5% stakeTango Therapeutics
5% stakeTango Therapeutics
TNGX
6% stake
9,742,402.8 sh
6% stake
Filed 08/14
